🇺🇸 FDA
Pipeline program

First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer

OKI-219-101

Phase 1 other active

Quick answer

First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer for Advanced Solid Tumors, Advanced Breast Cancer is a Phase 1 program (other) at OnKure Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
OnKure Therapeutics
Indication
Advanced Solid Tumors, Advanced Breast Cancer
Phase
Phase 1
Modality
other
Status
active

Clinical trials